Patents Assigned to Infinity Pharmaceuticals, Inc.
  • Combination therapies
    Patent number: 11944631
    Abstract: Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor or a pharmaceutically acceptable form thereof, and a Bcl-2 inhibitor or a pharmaceutically acceptable form thereof. Also provided herein are methods for treating cancer comprising administration the compositions, and uses of the compositions, e.g., for the treatment of cancer.
    Type: Grant
    Filed: August 2, 2021
    Date of Patent: April 2, 2024
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Jeffery L Kutok, Howard M. Stern
  • Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
    Patent number: 11939333
    Abstract: Solid forms of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphic forms, cocrystals, and amorphous forms thereof, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: March 26, 2024
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Louis Grenier, Andre Lescarbeau, Praveen Sharma, Daniel G. Genov
  • TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS
    Publication number: 20230364097
    Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders.
    Type: Application
    Filed: December 12, 2022
    Publication date: November 16, 2023
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Howard M. STERN, Jeffery L. Kutok
  • Methods of use of cyclopamine analogs
    Patent number: 11602527
    Abstract: The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: March 14, 2023
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Michael J. Grogan, Karen J. McGovern, Martin R. Tremblay
  • Heterocyclic compounds and uses thereof
    Patent number: 11541059
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: January 3, 2023
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Jeffery L. Kutok, David G. Winkler, Vito J. Palombella, Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Martin R. Tremblay
  • Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
    Patent number: 11312718
    Abstract: Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: April 26, 2022
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Pingda Ren, Michael Martin, Paul Isbester, Benjamin S. Lane, Jason Kropp
  • Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
    Patent number: 11247995
    Abstract: Solid forms of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphic forms, cocrystals, and amorphous forms thereof, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: February 15, 2022
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Louis Grenier, Andre Lescarbeau, Praveen Sharma, Daniel G. Genov
  • Combination therapies
    Patent number: 11147818
    Abstract: Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor, or pharmaceutically acceptable form thereof, in combination with a second agent, or a pharmaceutically acceptable form thereof, wherein the second agent is chosen from one or more of 1) a checkpoint modulator, 2) an XPO1 inhibitor, 3) an anti-CD19 antibody, 4) a TLR agonist, 5) a STING agonist, or 6) a Flt3 ligand, or a combination thereof. Also provided herein are methods of treatment comprising administration of the compositions, and uses of the compositions, e.g., for treatment of cancer.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: October 19, 2021
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventor: Jeffery L. Kutok
  • Combination therapies
    Patent number: 11110096
    Abstract: Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor or a pharmaceutically acceptable form thereof, and a Bcl-2 inhibitor or a pharmaceutically acceptable form thereof. Also provided herein are methods for treating cancer comprising administration the compositions, and uses of the compositions, e.g., for the treatment of cancer.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: September 7, 2021
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Jeffery L. Kutok, Howard M. Stern
  • Cyclopamine analogs
    Patent number: 11007181
    Abstract: The invention provides derivatives of cyclopamine having the following formula:
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: May 18, 2021
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Brian Austad, Mark L. Behnke, Alfredo C. Castro, Michael J. Grogan, Somarajannair Janardanannair, Andre Lescarbeau, Stephane Peluso, Andre B. Charette, Martin R. Tremblay
  • Heterocyclic compounds and uses thereof
    Patent number: 10941162
    Abstract: Trisubstituted bicyclic heterocyclic compounds (e.g., pyridopyrimidinones) and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: March 9, 2021
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Catherine A. Evans, Martin R. Tremblay
  • Heterocyclic compounds and uses thereof
    Patent number: 10919914
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: February 16, 2021
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Catherine A. Evans, Martin R. Tremblay
  • Methods of use of cyclopamine analogs
    Patent number: 10821102
    Abstract: The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: November 3, 2020
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Michael J. Grogan, Karen J. McGovern, Martin R. Tremblay
  • Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
    Patent number: 10759806
    Abstract: Provided are isotopologues of isoquinolinone and quinazolinone compounds of formula (AB?) that modulate PI3 kinase activity, processes for the preparation of the compounds, pharmaceutical compositions comprising the compounds, and methods of treatment of diseases and disorders using the compounds or pharmaceutical compositions.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: September 1, 2020
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventor: Catherine A. Evans
  • Heterocyclic compounds and uses thereof
    Patent number: 10675286
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: June 9, 2020
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Jeffery L. Kutok, David G. Winkler, Vito J. Palombella
  • Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof
    Patent number: 10550122
    Abstract: Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including Pl3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: February 4, 2020
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Pingda Ren, Michael Martin, Paul Isbester, Benjamin S. Lane, Jason Kropp
  • Cyclopamine analogs
    Patent number: 10406139
    Abstract: The invention provides derivatives of cyclopamine having the following formula:
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: September 10, 2019
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Brian Austad, Mark L. Behnke, Alfredo C. Castro, Michael J. Grogan, Somarajannair Janardanannair, Andre Lescarbeau, Stephane Peluso, Andre B. Charette, Martin R. Tremblay
  • Heterocyclic compounds and uses thereof
    Patent number: 10329299
    Abstract: Provided herein are compounds of Formula (I?) or (A?), pharmaceutical compositions comprising the compounds, and methods of use thereof. The compounds provided herein modulate kinase activity, including PI3 kinase activity, and are useful for treating diseases and conditions associated with kinase activity, including PI3 kinase activity.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: June 25, 2019
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Martin R. Tremblay
  • Methods of use of cyclopamine analogs
    Patent number: 10314827
    Abstract: The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: June 11, 2019
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Michael J. Grogan, Karen J. McGovern, Martin R. Tremblay
  • Heterocyclic compounds and uses thereof
    Patent number: 10253047
    Abstract: Trisubstituted bicyclic heterocyclic compounds (e.g., chromenones and quinolines) and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: April 9, 2019
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Catherine A. Evans, Martin R. Tremblay